Håkan Mellstedt/Anders Österborgs forskargrupp

This page in English

Professor, senior

Håkan Mellstedt

Telefon: 08-517 746 41
Enhet: Forskargrupp Mellstedt, Håkan
E-post: Hakan.Mellstedt@ki.se

Mer information finns på den engelska sidan.

Utvalda publikationer

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
Wierda W, Kipps T, Mayer J, Stilgenbauer S, Williams C, Hellmann A, et al
J. Clin. Oncol. 2010 Apr;28(10):1749-55

Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells.
Choudhury A, Derkow K, Daneshmanesh A, Mikaelsson E, Kiaii S, Kokhaei P, et al
Br. J. Haematol. 2010 Nov;151(4):327-35

Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study.
Rieger M, Osterborg A, Pettengell R, White D, Gill D, Walewski J, et al
Ann. Oncol. 2011 Mar;22(3):664-70

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.
Wierda W, Padmanabhan S, Chan G, Gupta I, Lisby S, Osterborg A, et al
Blood 2011 Nov;118(19):5126-9

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.
Bagnara D, Kaufman M, Calissano C, Marsilio S, Patten P, Simone R, et al
Blood 2011 May;117(20):5463-72

Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.
Daneshmanesh A, Hojjat-Farsangi M, Khan A, Jeddi-Tehrani M, Akhondi M, Bayat A, et al
Leukemia 2012 Jun;26(6):1348-55

Epithelial cell adhesion molecule expression (CD326) in cancer: a short review.
Patriarca C, Macchi R, Marschner A, Mellstedt H
Cancer Treat. Rev. 2012 Feb;38(1):68-75

Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.
Sylvan S, Rossmann E, Mozaffari F, Porwit A, Norin S, Karlsson C, et al
Br. J. Haematol. 2012 Dec;159(5):608-12

Outcomes of patients with fludarabine-refractory chronic lymphocytic leukaemia (CLL) – a population-based study from a well-defined geographic region. 
Eketorp Sylvan S, Hansson L, Karlsson C, Norin S, Lundin J, Österborg A
Leuk Lymph, in press 2013

The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells.
Hojjat-Farsangi M, Khan AS, Daneshmanesh AH, Moshfegh A, Sandin Å, Mansouri L, et al.
PLOS ONE, Vol 8, Iss. 10, e78339, 2013